

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

LAPSE OF TERM SHEET IN RELATION TO THE PROPOSED ACQUISITION OF ELPIS BIOPHARMACEUTICALS PTE. LTD.

The board of directors (the “**Board**” or the “**Directors**”) of Clearbridge Health Limited (the “**Company**”) refers to the Company’s announcement dated **28 April 2025** in relation to the entry into a binding term sheet (the “**Term Sheet**”) for the proposed acquisition of Elpis Biopharmaceuticals Pte. Ltd. (the “**Proposed Acquisition**”).

The Board wishes to announce that the Term Sheet has lapsed upon the long stop date of 23 January 2026, in accordance with its terms, and shall thereafter cease to have any further force or effect.

The lapse of the Term Sheet is not expected to have any material impact on the net tangible assets or earnings per share of the Company and its subsidiaries for the current financial year ending 31 December 2026.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

23 January 2026

*This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.